The multiple endocrine neoplasia (MEN) syndromes present a diverse array of challenges to the anesthesiologist. The tumors and their effects are often underdiagnosed and potentially discovered only when the patient is undergoing surgery for either a component of one of the syndromes or another procedure altogether. This can present the anesthesiologist with a life-threatening situation in the operating room. A thorough understanding of the syndromes, as well as management strategies, will enable the anesthesiologist to handle these patients.
Introduction
Multiple endocrine neoplasias (MEN) describe three distinct neoplastic syndromes involving more than one endocrine gland, inherited as autosomal dominant traits. The tumors often cause abnormal increases of hormone synthesis, which may remain clinically silent or produce life-threatening syndromes [1 ] . The anesthetic concerns result from the functional components of the syndrome. For purposes of this review, I will presume that for those with functional tumors the appropriate diagnostic and localization studies have been completed and I shall focus on the specific issues that confront the anesthesiologist in the operating room. Emphasis will be placed on those syndromes that have the potential to cause the most morbidity to the patient. For completeness, brief mention will be made of the other components.
MEN type 1 (MEN 1; Wermer's syndrome) is a rare disease which includes tumors of the parathyroid glands (95%), pancreatic islet cells (50%), and anterior pituitary tumors (30%). The tumors are due to inactivation of the MEN 1 oncosuppressor gene located on chromosome 11q13 [1 ,2 ,3,4] .
MEN type 2 (MEN 2)-associated tumors result from oncogenic point mutations of the c-Ret proto-oncogene located on chromosome 10cen-10q11.2. Three clinical subtypes have been described. MEN 2A (Sipple's syndrome) is characterized by the association of medullary thyroid cancer (97%) with pheochromocytoma (50%) and hyperparathyroidism (20%). MEN 2B (5% of cases) describes medullary thyroid cancer in association with pheochromocytoma, a Marfanoid body habitus, mucosal neuromas, and intestinal ganglioneuromas, referred to as the mucosal neuronal syndrome. Parathyroid involvement is rare. Familial medullary thyroid cancer is a variant in which medullary thyroid cancer is the only manifestation [1 ,2 ,4] .
Parathyroid tumors
Primary hypercalcemia is due to excess secretion of parathyroid hormone (parathormone), normally controlled by a negative feedback mechanism dependent on plasma calcium, overwhelming the kidneys' capacity to excrete the excess calcium. In MEN 1 and 2A, primary hyperparathyroidism is common, and may be the earliest manifestation. Most patients with parathyroid involvement have asymptomatic hypercalcemia, low serum phosphate levels, and elevated parathyroid hormone. However, they can present with a broad spectrum of symptoms, such as fatigue, weakness, confusion, lethargy, proximal muscle weakness, hyporeflexia, pseudogout, anemia, subperiosteal bone resorption, renal stones, polyuria, and polydipsia. Acutely it may be associated with hypertension, gastrointestinal disturbances, pancreatitis, and peptic ulcer disease. Bone pain and pathologic fractures may be present. Hypercalcemia can be detected on the electrocardiogram as a shortened QT interval, while the PR interval may be prolonged [5, 6] .
When symptomatic, lowering of plasma calcium concentrations is initially accomplished by establishing a diuresis with normal saline hydration to enhance renal calcium excretion, and may be followed by the use of diuretics. When necessary, rapid lowering can be accomplished by the use of intravenous mithramycin or bisphosphonates, which inhibits osteoclastic activity by parathyroid hormone, or hemodialysis [3, 5, 6] .
Management of anesthesia requires maintenance of hydration with sodium-containing solutions (by dilution and to inhibit renal reabsorption of calcium) and urinary output, with due consideration of possible co-existing renal dysfunction. The main risk in anesthetizing the hypercalcemic patient is the potential for cardiac dysrhythmias [6] . Monitoring of the QT intervals may not reflect changes in plasma calcium concentrations. Fortunately, serious dysrhythmias from ventricular irritability are uncommon [7] . Unpredictable responses to muscle relaxants may occur. Pre-operative muscle weakness would suggest increased sensitivity to non-depolarizing muscle relaxants. Careful positioning is required due to the likely presence of osteoporosis and the potential for pathologic fractures [6] .
Successful surgery, usually excision of three and a half glands, is indicated by normalization of plasma calcium concentrations within 3 or 4 days. Postoperatively, transient mild hypocalcemia occurs and neuromuscular irritability, seizures, or laryngeal spasm are possible [3, 5, 6] . For the anesthesiologist, the most important operative complication is injury to the recurrent laryngeal nerve, which innervates both the adductor and abductor muscles of the larynx and vocal cords. Damage may cause hoarseness or stridor or even complete airway obstruction, either upon extubation or in the post-anesthesia care unit. Injury to the superior laryngeal nerve causes loss of sensation in the larynx and piriform sinus, predisposing the patient to aspiration postoperatively [6] . After surgery-induced vocal-cord motion impairment, recovery may occur such that the patient regains a satisfactory voice and safe airway, although mild persistent impairment may result in recurrent aspiration. The airway may also become compromised by hematoma formation compressing the trachea. A tracheostomy may be required [5, 6, 8 ] .
Pancreatic islet cell tumors
Duodenopancreatic tumors are the second most common manifestation of MEN 1. The islets of Langerhans represent the endocrine portion of the pancreas. During stimulation or suppression tests, usually more than one hormone is secreted; however, patients usually present with symptoms of excess of one hormone [3] . In association with MEN, the most common islet cell tumors are insulinomas and gastrinomas. Other hormone-secreting tumors are quite rare and do not present significant problems to the anesthesiologist, but are mentioned for completeness.
Insulinomas
Hypersecretion of insulin by islet b-cell tumors may produce severe fasting hypoglycemia [6, 9] . Symptoms occur several hours after eating, with manifestations of excess epinephrine levels, tremulousness, tachycardia, palpitations, and diaphoresis. Patients may also present with changes in mental status, seizures, or other evidence of central-nervous-system damage. The diagnosis is made in the presence of Whipple's Triad, symptoms associated with hypoglycemia, relieved with increased blood glucose levels, inappropriately elevated plasma insulin and C-peptide, and absence of sulfonylurea [9] .
The major challenge during anesthesia is maintenance of normal blood glucose concentrations to prevent cerebral damage. Anesthetic technique should focus on agents that decrease the cerebral metabolic rate for oxygen (CMRO 2 ); therefore, for example, ketamine as an induction agent should be avoided. Normocarbia should be maintained during controlled ventilation. The patients may be obese as they attempt to maintain normal blood glucose values with frequent meals; thus careful attention must be paid to the airway, and attendant ventilatory and cardiac issues must be addressed. The patient should also be evaluated preoperatively for the presence of neurologic damage. It is helpful to determine at what level of serum glucose symptoms occur to have a guideline for intraoperative management [9] .
Surgical manipulation of the tumor may cause profound hypoglycemia. An intra-arterial catheter should be placed prior to or immediately after induction as frequent serum glucose determinations will be required. Glucose should be included in the intravenous solutions intraoperatively as the signs of hypoglycemia (diaphoresis, hypertension, tachycardia) will be masked under anesthesia. Serum glucose should be maintained above the level at which the patient develops symptoms when awake. During operation, blood glucose concentrations will increase, probably due to increased sympathetic-nervous-system activity and release of epinephrine, glucagon, and cortisol. Following resection, hyperglycemia may result. A rise in the serum glucose after resection may be used as an indicator or adequate resection of the tumor [6, 9] . Glucose determinations should be continued postoperatively until serum levels stabilize [9] .
Gastrinomas
Zollinger-Ellison syndrome is a clinical syndrome characterized by peptic ulcer disease, diarrhea, and esophageal reflux. This is due to hypersecretion from a gastrin-releasing endocrine tumor located in the pancreas or duodenum. Zollinger-Ellison syndrome is the most common functional pancreatic endocrine tumor seen in MEN 1 patients. They often present with renal stones from hypercalcemia, and abdominal pain. Medical therapy with H2 receptor antagonists and proton-pump inhibitors may be effective initially. The tumor is as often found in the duodenum as in the pancreas.
Patients may have large gastric fluid volumes from gastric hypersecretion making them vulnerable to aspiration during anesthetic induction. Esophageal reflux is common. Rapid sequence induction with maintenance of cricoid pressure is indicated. Hypovolemia and electrolyte imbalance (hypokalemia and metabolic alkalosis) may accompany profuse, watery diarrhea and should be corrected prior to surgery [6] .
Glucagonoma
Glucagon is produced in the A cells in the periphery of the islets, and regulates hepatic glucose production.
Patients frequently have a characteristic erythematous, necrolytic rash located on the face, intertriginous areas, and extremities. Plasma glucagon is elevated. Mild diabetes mellitus is detected by an abnormal glucosetolerance test. Ketoacidosis does not occur. Patients may also have thromboembolic disease, weight loss, and anemia. Octreotide (see below) is effective in reducing glucagon levels and symptoms [6] .
Somatostatinoma
Somatostatin, produced in the D cells of the islets, inhibits the secretion of insulin, glucagon, growth hormone, prolactin, gastrin, and secretin, and pancreatic exocrine secretion. Patients may present with diabetes, cholelithiasis, steatorrhea, weight loss, and anemia. Other hormones may be produced.
VIPoma
Vasoactive inhibitory polypeptide is a 28-amino-acid peptide which modulates vascular tone and water and ion transport. It produces severe secretory diarrhea, hypokalemia, and metabolic acidosis. Patients may present with profound weakness, flaccid paralysis, and hypokalemic nephropathy. These tumors are rarely associated with MEN I syndrome. Octreotide reduces output of the tumor [6] .
Nonfunctioning islet cell tumors
These frequently present as large metastatic masses in the liver. Patients may present with malaise, jaundice, and abdominal pain.
Carcinoid tumors
Primary carcinoid tumors are neuroendocrine in origin, and are found primarily in the gastrointestinal tract. They arise from enterochromaffin cells and maintain the capacity for amine precursor uptake and decarboxylation (APUDomas), the ability to synthesize and secrete peptide hormones and monoamines, vasoactive substances, such as 5-hydroxytryptamine (serotonin) and tachykinins (substance P), prostaglandins, histamine, and kallikreins [5, 6, [10] [11] [12] . They frequently arise from the small intestine, or less often from organs derived from the embryonic foregut (bronchus, stomach, pancreas, thyroid) or ovarian or testicular teratomas [10, 12] .
Patients with the carcinoid syndrome most commonly present with cutaneous flushing of the head and neck, associated with tachycardia, normo-or hypotension, lacrimation, and periorbital edema. They commonly have telangiectasia of the face and neck and intestinal hypermotility with acute or chronic diarrhea. Abdominal pain, dehydration, and electrolyte abnormalities may be present [5, 6, [10] [11] [12] [13] . Endocardial thickening, particularly of the right side of the heart, leading to valvular malfunction, decreased myocardial compliance, and high cardiac output from vasodilator release constitute carcinoid heart disease. There can also be left-sided cardiac involvement, with decreased ventricular compliance and fibrosis of the mitral or aortic valves [5, 10, 11, 13] .
Serotonin is the most common mediator secreted. It is formed from tryptophan, degraded by monoamine oxidase, and ultimately converted to 5-hydroxyindolacetic acid which can be detected in the urine and is a predictor of perioperative complications, although up to 20% of patients may have normal urinary 5-hydroxyindolacetic acid levels [10, 11, 13] . Serotonin can cause vasoconstriction or vasodilation, and may be responsible for hypertension or hypotension. It increases intestinal hypermotility and causes diarrhea, as well as hypoproteinemia and hyperglycemia. It also causes positive inotropy and chronotropy in the myocardium, and is thought to be responsible for carcinoid heart disease [10] [11] [12] .
Histamine release is common in patients with foregut carcinoids. Normal gastric mucosa contains histidine decarboxylase, which may explain this association. It may be responsible for bronchospasm and flushing [10, 11] .
Kallikreins are enzymes that generate kinins from kininogens. Bradykinin causes vasomotor relaxation, hypotension, bronchospasm, and flushing. Although it is normally removed rapidly from the circulation, when release is massive, plasma kininase and aminopeptidase become overwhelmed and an exaggerated and prolonged response occurs. Tachykinins (neuropeptide K, neurokininA, vasoactive intestinal polypeptide, and substance P) may be involved with flushing and cardiac effects [10, 11] .
Normally, release of these substances produces minimal symptoms. Manifestations occur when the liver is unable to inactivate these substances before they reach the systemic circulation. Thus the syndrome is usually seen with liver metastases and primary carcinoid tumors located outside of the gastrointestinal tract [10, 11, 12] .
Anesthetic considerations begin with the evaluation of the patient for the presence of the carcinoid syndrome and carcinoid heart disease. Cardiovascular status, intravascular volume, and the possible existence of electrolyte abnormalities, bronchospasm, or hyperglycemia should be assessed with the appropriate studies and the patient's condition optimized. Physical or pharmacological triggers of histamine or catecholamine release should be avoided. Preoperatively, the patients should be treated with a variety of drugs to block the production, release, or effect of mediators secreted by the tumor [10] . Combination H1 and H2 blockers may be effective, as well as corticosteroids or serotonin blockers, such as ketanserin or cyproheptadine, to counter gastrointestinal manifestations. Treatment of bronchospasm with b-adrenergic agonists may exacerbate histamine release. Somatostatin, an antisomatropin (anti-growth hormone) and gastrointestinal regulatory peptide reduces release of various vasoactive peptides from the endocrine tissues, but has a very short half life and must be given by infusion. Octreotide, a synthetic somatostatin analogue, has proved invaluable in the treatment, pre-and intraoperatively, of the carcinoid syndrome due to its ability to prevent regulatory peptide release from the gastropancreatic system. It is given subcutaneously in a dose range from 50 to 500 mg every 8 h [11] . It is used to control flushing, diarrhea, bronchospasm, and hypo-and hypertension [10, 14] . Its use intraoperatively is associated with a decreased frequency of complications. Aprotinin, a kallikrein inhibitor, has also been used to treat flushing associated with bradykinin production, with variable success [10, 11, 13] . Antibiotic prophylaxis will be required should valvular heart disease be present [5, 12] .
Preoperative sedation with a benzodiazepine is used to minimize stress-induced catecholamine release. Other medications used to control mediator release should be continued. Octreotide can also be used as a premedication. The anesthetic goal is to prevent the release of mediators by using octreotide and avoiding triggers [10, 11] . Invasive arterial monitoring should be established prior to induction. Central venous access should be considered in anticipation of large blood loss where the physiologic responses to hypovolemia are distorted by the effects of the released mediators. Induction agents and muscle relaxants with minimal hemodynamic side effects should be titrated in slowly. Drugs that stimulate the sympathetic nervous system (ketamine, pancuronium) or histamine release (morphine, meperidine, atracurium, mivacurium, D-tubocurarine) should be avoided [11] . Propofol may be the best induction agent, as it suppresses laryngeal reflexes in response to intubation and does not release histamine, as, for example, thiopentone can. Etomidate is not as effective at blunting the hypertensive response to intubation [10, 11] . Mediator release from abdominal fasciculations after succinylcholine use seems to be of only theoretical concern. Regional anesthesia with its unpredictable hypotension is not recommended as both the decreased blood pressure and the need for sympathomimetic drugs may also trigger mediator release [5, 6, 11, 12] . The patient should be kept warm, as hypothermia is also a trigger of peptide release [10] . Increased sedation due to central-nervous-system levels of serotonin may decrease anesthetic requirements as well as cause delayed awakening postoperatively [10] [11] [12] .
A 'carcinoid crisis', consisting of hyper-or hypotension, bronchospasm, hypoglycemia, cardiac dysrhythmias, or heart failure may occur at any time perioperatively, but usually in response to induction, tracheal intubation, surgical stimulation, or drugs causing mediator release. Hypertension may be treated by increasing depth of anesthesia, use of b-blocking agents or octreotide [10, 11, 14] . Hypotension is more difficult to treat because of the contraindication to the use of sympathomimetics. Close communication with the surgeon is required, as surgical manipulation should be stopped until the patient is stabilized. Octreotide is the most effective agent to prevent and treat carcinoid crisis. It effectively controls flushing, hypotension, wheezing, and diarrhea in most patients. It can be given intravenously by bolus injection (10 mg) or run as an infusion [5, 10, 11, 12] . In the presence of bronchospasm, b-2 adrenergic agonists, theophylline, and epinephrine are contraindicated as they may further stimulate mediator release. Corticosteroids, ipratropium bromide, and antihistamines may be used [10] [11] [12] .
The effects of mediators continue even after tumor removal. Undetected metastases may be present. Therefore, octreotide should be continued into the postoperative period and weaned over the course of a week or so. Avoidance of triggers also should be continued [10] .
Anterior pituitary tumors
Anterior pituitary tumors are a feature of MEN 1. They may present with endocrine or neurologic signs. The order of frequency of occurrence is prolactinomas (58%), then tumors producing excess growth hormone (23%), and nonsecreting adenomas (10%) [3] .
Prolactinomas
Prolactinomas, neoplasms of the lactotrope cells, are most common. In premenopausal women, hyperprolactinemia causes galactorrhea and oligomenorrhea. In men, hypogonadism and low testosterone levels are found. When symptomatic, they may be treated with dopamine agonists, such as bromocriptine or pergolide. Prolactinomas are the only tumors that can be treated medically. If unresponsive, trans-sphenoidal surgery is required [3] .
Acromegaly
Proliferation of somatotrope cells producing excess growth hormone results in acromegaly in adults and gigantism in children. Patients are frequently diagnosed because of changes in the face, including prognathism, enlargement of the nose and lips, frontal bossing from enlargement of the sinuses, dental malocclusion, increased spacing between the teeth, and enlargement of the tongue, epiglottis, and lower jaw [6, 15, 16] . Sleep apnea can occur due to the latter as well as changes in the soft tissues of the hypopharynx. Hoarseness and abnormal movement of the vocal cords may occur. The hands and feet also increase in size. Skeletal problems include arthritis, backache, and a marked kyphoscoliosis [15] .
Patients with acromegaly have increased morbidity and mortality due to diabetes, cardiac hypertrophy, hypertension, and dysrhythmias from sleep apnea, coronary disease, congestive heart failure, colon cancer, and stroke. Peripheral neuropathy due to nerve trapping from soft tissue overgrowth is common, and flow through the ulnar artery may be impaired [6, 15] . Visceromegaly also occurs. Enlarged lung volumes may lead to ventilation perfusion mismatch and increased dead space. Glucose intolerance may occur. They may also present with headache, visualfield defects, and rhinorrhea from extension of the adenoma. Treatment can result in resolution of soft-tissue changes, improvement in metabolic derangement, and reduction in excess morbidity [15] .
The primary impact on anesthetic management is from changes in the upper airway. Mask fit and ventilation may be difficult. Increased size of the tongue and epiglottis predisposes the patient to upper-airway obstruction and difficulties with visualization of the vocal cords and intubation. Enlarged vocal cords and structural changes in the larynx may cause glottic narrowing. The nasal turbinates may be enlarged. Skeletal changes will cause decreased neck mobility [15, 17] . Fiberoptic intubation may be necessary, but may prove difficult in these patients because of distorted anatomy and resistance to advancement of the endotracheal tube [16] . Upon extubation, the large tongue may cause airway collapse. If placement of an arterial monitor is needed, inadequate collateral circulation at the wrist must be considered. If diabetes mellitus is present, blood glucose levels will need to be monitored. Patients with sleep apnea are usually not premedicated so as to avoid further airway compromise [15, 16] .
Adrenocortical hyperfunction
Hypersecretion of adrenocorticotropic hormone (corticotropin) stimulates the adrenal gland to produce cortisol, androgens, and to a lesser extent mineralocorticoids. Cushing's disease, the result of excess production of adrenocorticotropic hormone by a pituitary neoplasm, has many features. Those most characteristic of the disease include the 'buffalo hump' and increased supraclavicular fat, centripetal fat distribution with thin extremities, and 'moon facies'. The patients may also be hypertensive, and have hirsutism, thin skin with purple striae, easy bruising, acne, proximal muscle weakness, osteoporosis, emotional lability, psychosis, hypokalemic metabolic alkalosis, hyperpigmentation, glucose intolerance, increased susceptibility to infection, and impaired wound healing. They may also present with tumor mass effects such as headaches, hypopituitarism, and visualfield loss [5] .
Management of anesthesia is based on addressing the effects of excess cortisol. Evaluation of cardiovascular function, electrolytes, and plasma glucose are required. Cortisol release will be increased during surgical stimulation. Skeletal muscle weakness may affect the responses to muscle relaxants [6] . Stress-dose steroids will be required intraoperatively [5] .
Medullary thyroid carcinoma
Medullary thyroid carcinoma is a tumor of the C cells, increasing secretion of calcitonin, inhibiting osteoclasts and decreasing bone resorption, thereby decreasing serum calcium concentration. It is present in all patients with MEN 2, and frequently associated with pheochromocytoma. Bilateral tumors are common, so that total thyroidectomy is required. The gland is rarely enlarged enough to cause airway compromise. Of anesthetic concern is intraoperative damage to the recurrent laryngeal nerve (see above under parathyroid tumors), which innervates both the adductor and abductor muscles of the larynx and vocal cords. Damage may cause anything from hoarseness to stridor and complete airway obstruction upon extubation of the trachea, or in the post-anesthesia care unit. The airway may also become compromised by hematoma formation compressing the trachea. Injury to the superior laryngeal nerve causes loss of sensation in the larynx and piriform sinus, predisposing the patient to aspiration postoperatively [5, 6, 8 ] .
Pheochromocytoma
Pheochromocytomas are functionally active tumors of the chromaffin cells presenting with signs and symptoms of excess catecholamine release, particularly paroxysmal hypertension. They are a component of MEN 2. Tumors are usually located in the adrenal glands and may be bilateral, or they may be extra-adrenal (paragangliomas) and arise from the chromaffin tissue along the paravertebral sympathetic chain from the base of the skull to the pelvis, near the aortic bifurcation, urinary bladder, or other autonomic ganglia. Intracardiac pheochromocytomas exist but are quite rare [5,6,12,18 ,19,20] . Pheochromocytomas pose a severe and unpredictable threat to the patient's life, making it necessary to begin medical therapy as soon as the diagnosis is made. Surgery can be performed when the patient is properly prepared [5,6,12,18 ,19,20] .
The classic presentation is paroxysms of hypertension associated with the triad of palpitations, diaphoresis, and headache. Patients may also present with apprehension or anxiety, tremulousness, weakness, and weight loss [12, 20] . The cardinal sign is severe and refractory hypertension that may worsen in patients receiving badrenergic antagonists or guanethidine. Orthostatic hypotension is common, reflecting decreased intravascular fluid volume [5, 6] . Patients may experience a precipitous drop in blood pressure when treated with a-adrenergic antagonists.
Preoperative assessment begins with the evaluation of end-organ damage [12] . Persistent hypertension may lead to a hypertrophic cardiomyopathy, congestive heart failure, myocardial infarction, renal failure, or cerebral hemorrhage. A dilated cardiomyopathy is less often seen. The electrocardiogram may reveal high QRS amplitudes, ST-T segment changes, or prolongation of the QT interval. Catecholamine secretion also causes hyperglycemia due to glycogenolysis and inhibition of insulin release. It rarely requires treatment with insulin and usually resolves after resection [5,6,18 ,19,20] .
Patients will be volume-contracted as well as desensitized to catecholamines. Preoperative preparation begins with a-adrenergic blockade for 1-4 weeks, usually with oral phenoxybenzamine, a noncompetitive a-1 blocker. The end point is normalization of blood pressure and prevention of paroxysms of hypertension and tachycardia, without inducing severe orthostatic hypotension [18 ,19] . Satisfactory treatment is considered to be present when the patient has sinus congestion, sustained blood pressure measurements below 160/90 mHg, orthostatic hypotension, absence of ST-T segment abnormalities on the electrocardiogram, and only rare premature ventricular contractions. Selective postsynaptic a-1 antagonists, such as prazosin or doxazosin, can also be used. Their advantages over phenoxybenzamine include lack of production of reflex tachycardia and shorter duration of action, minimizing postoperative hypotension and fluid requirements. a-Blockade prevents catecholamine-induced vasoconstriction, allowing normotension to return and volume contraction to correct itself [5, 6, 12, 19, 20] . A reduction in hematocrit should be seen. If tachycardia and dysrhythmias persist, b-blockade is instituted, but only after a-blockade has been established so as to prevent unopposed a-vasoconstriction and exacerbation of hypertension or potentially cardiac failure. b-Adrenergic antagonists should be used carefully in patients with a dilated cardiomyopathy [5,12,18 ,19,20] . Calcium-channel blockers have been used in patients with paroxysmal hypertension who are otherwise normotensive, without production of orthostatic hypotension [19] . Lidocaine and amiodarone have been used to control tachyarrhythmias. If combined management is not effective, a-methyl-paratyrosine, which competitively inhibits tyrosine hydroxylase, the rate-limiting step in catecholamine synthesis, may be added. It reduces tumor stores of catecholamines and may be useful in patients with congestive heart failure [19] . a-Blockade is continued until surgery. The patient should be premedicated with a benzodiazepine in order to reduce apprehension-induced activation of the sympathetic nervous system [5, 6, 12] . Anesthetic management is guided by techniques that prevent catecholamine release or mitigate their dysrhythmic effects. Severe and lifethreatening hypertension originates from either noxious stimuli or release of catecholamines from excessive stores in adrenergic nerve endings, as occurs during induction, intubation, and tumor palpation [19] .
After placement of the usual monitors and prior to induction of anesthesia, the patient should be further sedated and an intra-arterial catheter placed. Induction agents are then titrated carefully to maintain normotension with both a short-acting narcotic such as fentanyl, and a sedative/hypnotic such as a barbiturate, propofol, or etomidate, until the patient loses consciousness. After adequate depth of anesthesia is achieved, endotracheal intubation is facilitated by the use of nondepolarizing muscle relaxants such as vecuronium or rocuronium, selected to produce minimal cardiovascular effects via histamine release or vagolytic properties. Also, catecholamine-reuptake inhibitors should not be used. The use of succinylcholine has the theoretical disadvantage of potential release of catecholamines from skeletal muscle contractions. A second intravenous line may be placed for infusions, especially if nitroprusside is going to be used. Acutely, intravenous nitroprusside (1-2 mg/kg), phentolamine (non selective a-blocker), or sublingual nifedipine (calcium-channel blocker) may be needed [12, 19] .
Anesthesia is maintained with intravenous and inhalational agents that do not sensitize the heart to the dysrhythmic effects of catecholamines. Their ability to rapidly adjust the depth of anesthesia in response to changes in blood pressure is ideal. Regional anesthesia has been used but probably is not the best choice, as postsynaptic a-adrenergic receptors can still respond to direct effects of increased circulating catecholamines. In addition, hypotension after the tumor is resected may be difficult to correct due to the absence of sympatheticnervous-system activity [12, 19] .
We have found that close communication with the surgeon obviates the need for the use of almost any agent other than phentolamine and labetalol. This approach prevents rapid changes in blood pressure from over-or undercorrection. Our technique is to titrate in 5 mg of phentolamine after induction, prior to mobilization of the tumor. When the surgeon gets close to or begins to manipulate the tumor and the pressure starts to rise, we ask him to stop working until we again achieve control with the above medications. Then the procedure is resumed. We continue this way until the tumor is resected, at which time more aggressive hydration is begun, if needed. The use of central venous monitoring is guided by patient preoperative status, but is not required usually [21 ] .
When the venous outflow from the tumor is ligated, patients will require volume expansion with normal saline, the degree of which will depend on pre-operative hydration status, residual effects of a-blockade, increased venous capacitance, and surgical blood loss. Several liters may be needed. Pressors such as norepinephrine, phenylephrine, or dopamine can be added if necessary, but are generally ineffective and contraindicated in the presence of hypovolemia. A pulmonary artery catheter may be considered if the patient has a history of congestive heart failure [6, 19] . However, transesophageal echocardiography may be more useful [22] .
Postoperatively, patients may remain hypertensive for several weeks, even after complete resection, although the presence of a second unidentified pheochromocytoma must be considered. Hypotension due to hypovolemia or decreased sympathetic tone may occur. Blood glucose concentrations should be checked as hypoglycemia may occur after resection, due to rebound hyperinsulinism from the withdrawal of the inhibitory effect of norepinephrine on insulin secretion. b-Blockade may mask the clinical symptoms of hypoglycemia. After bilateral adrenalectomies, patients will require steroid replacement [12, 19] .
Mucosal neuronal syndrome
A component of MEN 2B, this syndrome consists of neuromas most commonly located in the oral cavity and eyes. It is also associated with gastrointestinal tract abnormalities, especially gastrointestinal ganglioneuromatosis, which can occur from the esophagus to the large intestine. Associated symptoms are swallowing abnormalities, megacolon, diarrhea, and constipation.
Patients may also have a Marfanoid habitus, with features including tall stature with long extremities, kyphosis, pectus excavatum or carinatum, pes cavus, and a high arched palate.
Conclusion
The MEN syndromes are a group of inherited disorders that present a variety of clinical challenges to the anesthesiologist. First is their underdiagnosis and potential discovery when the patient is undergoing surgery for another reason, and second is their proper management when specific resection is undertaken. Depending on the tumor, the anesthetic course may range from routine with no special requirements to severe and lifethreatening, necessitating care by an anesthesiologist experienced in these cases. Although some syndromes do demand specific management techniques, most often a carefully planned and thoughtfully administrated anesthetic is the key to a successful outcome.
